REGN - Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? | Benzinga
4D Molecular Therapeutics (NASDAQ:FDMT) shares are trading higher after the company released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.
Data presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference consisted of 24-week landmark results from the PRISM clinical trial’s randomized Phase 2 Dose Expansion cohort.
A single intravitreal dose of 4D-150 demonstrated favorable safety results through the data cutoff date (all ophthalmic exams through up to 48 weeks of follow-up):
No significant intraocular inflammation
- High dose: None
- 97% (38 of 39 ...